LIXTE Biotechnology Holdings, Inc. announced the enrollment of the first patient in the Phase 1b portion of the Phase 1b/2 protocol (NCT05809830) to determine the appropriate dose of LB-100 given with a standard dose of doxorubicin. Once the dose is determined, a randomized Phase 2 study will be initiated seeking to gain evidence that the inclusion of doxorubicin increases time to a progression and/or overall survival of patients with advanced soft tissue sarcomas (ASTS).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.39 USD | -1.65% | +0.42% | +1.70% |
09/05 | Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
23/04 | Lixte Biotechnology Files Up to $50 Million Mixed Shelf | MT |
1st Jan change | Capi. | |
---|---|---|
+1.70% | 5.47M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol